Design, synthesis and biological evaluation of Chidamide derivatives against breast cancer
Bioorganic & Medicinal Chemistry Letters · 2026-08 · 137 · 130652
DOI: 10.1016/j.bmcl.2026.130652 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic & Medicinal Chemistry Letters, 2026-08. Verfasst von Ying Zhou und 8 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Jiangsu Ocean University, Lianyungang 222005, China. Hauptthemen laut MEDLINE: Benzamides, Aminopyridines, Antineoplastic Agents, Drug Design. Die Arbeit nennt 31 Literaturangaben.
Abstract (Originalsprache)
In this study, we designed and synthesized a series of compounds derived from the histone deacetylase inhibitor (HDACi) Chidamide and the BET bromodomain inhibitor (+)-JQ-1. All target compounds were structurally characterized by 1H NMR, 13C NMR, and high-resolution mass spectrometry (HRMS). Antiproliferative activity was assessed by an MTT assay in MDA-MB-231 (breast cancer), HeLa (cervical cancer), and HCT116 (colon cancer) cells, with chidamide and (+)-JQ-1 as reference compounds; cytotoxicity in 293 T cells was further evaluated to estimate selectivity. Results indicated that most derivatives exhibited superior activity to Chidamide, with compound 6e demonstrating the strongest inhibitory effect against MDA-MB-231 cells. The IC50 values of 6e were 0.10 ± 0.02 μM (MDA-MB-231), 0.90 ± 0.17 μM (HeLa), 19.60 ± 0.90 μM (HCT116), and 70.13 ± 5.19 μM (293 T). Further assays showed that 6e inhibited colony formation, migration, adhesion, and invasion of MDA-MB-231 cells in a concentration-dependent manner. Annexin V-FITC/PI flow cytometry indicated apoptosis induction. In the chicken embryo chorioallantoic membrane (CAM) model, 6e inhibited tumor growth and angiogenesis more effectively than chidamide. In summary, 6e demonstrates promising optimization potential as a lead compound for breast cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy, Jiangsu Ocean University, Lianyungang 222005, China.
- College of Pharmacy, Jiangsu Ocean University, Lianyungang 222005, China. Electronic address: wangxiujun@jou.edu.cn.
- College of Pharmacy and Chemistry & Chemical Engineering, Taizhou University, Taizhou, Jiangsu 225300, PR China. Electronic address: youyouyoualterl@163.com.
- College of Pharmacy and Chemistry & Chemical Engineering, Taizhou University, Taizhou, Jiangsu 225300, PR China. Electronic address: jijing@jou.edu.cn.
Zitieren
APA
Zhou, Y., Lang, Z., Lin, H., Wang, J., Zhang, B., Asan, K., Wang, X., Sun, L., & Ji, J. (2026). Design, synthesis and biological evaluation of Chidamide derivatives against breast cancer. Bioorganic & Medicinal Chemistry Letters, 137, 130652. https://doi.org/10.1016/j.bmcl.2026.130652
Vancouver
Zhou Y, Lang Z, Lin H, Wang J, Zhang B, Asan K, et al. Design, synthesis and biological evaluation of Chidamide derivatives against breast cancer. Bioorganic & Medicinal Chemistry Letters. 2026;137:130652. doi:10.1016/j.bmcl.2026.130652
BibTeX
@article{Zhou2026,
author = {Zhou, Ying and Lang, Ziyan and Lin, Haiyan and Wang, Jian and Zhang, Boyu and Asan, Kadirya and Wang, Xiujun and Sun, Lu and Ji, Jing},
title = {Design, synthesis and biological evaluation of Chidamide derivatives against breast cancer},
journal = {Bioorganic & Medicinal Chemistry Letters},
year = {2026},
volume = {137},
pages = {130652},
doi = {10.1016/j.bmcl.2026.130652}
}
EUVIMED